EA201391199A1 - Композиции из hyr1-производных и способы лечения ими - Google Patents

Композиции из hyr1-производных и способы лечения ими

Info

Publication number
EA201391199A1
EA201391199A1 EA201391199A EA201391199A EA201391199A1 EA 201391199 A1 EA201391199 A1 EA 201391199A1 EA 201391199 A EA201391199 A EA 201391199A EA 201391199 A EA201391199 A EA 201391199A EA 201391199 A1 EA201391199 A1 EA 201391199A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hyr1
treatment
derivatives
compositions
methods
Prior art date
Application number
EA201391199A
Other languages
English (en)
Other versions
EA025831B1 (ru
Inventor
Ашраф С. Ибрагим
Майкл Р. Йиман
Джон Е. Джр. ЭДВАРДС
Гуаньпиншэн Ло
Юэ Фу
Original Assignee
Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер filed Critical Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер
Publication of EA201391199A1 publication Critical patent/EA201391199A1/ru
Publication of EA025831B1 publication Critical patent/EA025831B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение предлагает выделенные полипептиды Hyr1. Изобретение также предлагает вакцины и антитела, подходящие для лечения или профилактики кандидоза или инфекций Acinetobacter или и того, и другого.
EA201391199A 2011-09-14 2012-09-14 Композиции из hyr1-производных и способы лечения ими EA025831B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161534734P 2011-09-14 2011-09-14
US201161564201P 2011-11-28 2011-11-28
PCT/US2012/055604 WO2013040478A2 (en) 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same

Publications (2)

Publication Number Publication Date
EA201391199A1 true EA201391199A1 (ru) 2014-04-30
EA025831B1 EA025831B1 (ru) 2017-02-28

Family

ID=47884005

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391199A EA025831B1 (ru) 2011-09-14 2012-09-14 Композиции из hyr1-производных и способы лечения ими

Country Status (11)

Country Link
US (1) US10160790B2 (ru)
EP (1) EP2755668A4 (ru)
JP (1) JP2014527084A (ru)
CN (1) CN103998049A (ru)
AU (1) AU2012308281A1 (ru)
BR (1) BR112014005773A2 (ru)
CA (1) CA2848403A1 (ru)
EA (1) EA025831B1 (ru)
GE (1) GEP20197052B (ru)
UA (1) UA115305C2 (ru)
WO (1) WO2013040478A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2968497B1 (en) 2013-03-15 2020-08-12 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP2942389A1 (en) * 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
GB201503812D0 (en) * 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
US11306137B2 (en) 2015-07-13 2022-04-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Antibody binding agents that bind Acinetobactor and uses thereof
CN108883167A (zh) 2016-03-09 2018-11-23 加州大学洛杉矶分校港口医学中心生物医学研究所 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒
GB201902769D0 (en) * 2019-03-01 2019-04-17 Univ Court Of The Univ Of Aberdeen Antibody molcules and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
AU2010266114B2 (en) 2009-07-03 2016-07-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center HYR1 as a target for active and passive immunization against Candida

Also Published As

Publication number Publication date
EA025831B1 (ru) 2017-02-28
US20150191514A1 (en) 2015-07-09
UA115305C2 (uk) 2017-10-25
GEP20197052B (en) 2019-12-25
AU2012308281A1 (en) 2014-04-24
US10160790B2 (en) 2018-12-25
BR112014005773A2 (pt) 2019-09-24
JP2014527084A (ja) 2014-10-09
WO2013040478A3 (en) 2013-06-27
EP2755668A4 (en) 2015-07-01
CN103998049A (zh) 2014-08-20
EP2755668A2 (en) 2014-07-23
WO2013040478A2 (en) 2013-03-21
CA2848403A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201590388A1 (ru) Способы лечения таупатии
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201591420A1 (ru) Гетероарильные соединения и их применение
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA201491505A1 (ru) Соединения для лечения спинальной мышечной атрофии
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
EA201201000A1 (ru) Способы лечения колоректального рака
WO2012173846A3 (en) Peptidomimetic macrocycles
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU